Top

Published in:

01-09-2019 | Metastasis | Original Research

Therapeutic value of postmastectomy radiation therapy for T1–2 breast cancer with 1–3 positive lymph nodes

Authors: Yuri Kimura, Shinsuke Sasada, Noriko Goda, Keiko Kajitani, Akiko Emi, Norio Masumoto, Takayuki Kadoya, Morihito Okada

Published in: Journal of Radiation Oncology | Issue 3/2019

Abstract

Purpose

Postmastectomy radiation therapy (PMRT) reduces locoregional recurrence (LRR) and breast cancer mortality for node-positive breast cancer, but its indication remains controversial in patients with 1–3 positive lymph nodes.

Methods

We retrospectively analyzed LRR and survival rates in T1–2 breast cancer with 1–3 positive lymph nodes according to PMRT. The prognostic factors and the impact of the current standard systemic therapy (early period: 2000–2007 and late period: 2008–2015) were assessed because adjuvant trastuzumab has only been approved in 2008 in Japan.

Results

Between 2000 and 2015, 162 patients with T1–2N1 breast cancer underwent mastectomy, and 32 (19.8%) underwent PMRT. The 5-year LRR rates were 5.3% in the no PMRT group and 0% in the PMRT group (P = 0.272). Meanwhile, the disease-free survival rates were 80.6% in the no PMRT group and 96.6% in the PMRT group (P = 0.095), and the benefit of PMRT was low in the late period. The significant prognostic factors were larger tumor size (T2) and estrogen receptor negativity.

Conclusions

PMRT tended to improve LRR and disease-free survival. The omission of PMRT is carefully determined.

NCCN Clinical Practice Guidelines in Oncology Breast Cancer 2017; 2018

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY et al (2016) Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol 34:4431–4442CrossRef

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E et al (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8–v30CrossRef

McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 383:2127–2135CrossRef

Ishikawa T, Kaise H, Yamada K, Hosonaga M, Chishima T, Narui K et al (2017) Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements. Breast Cancer 24:496–501CrossRef

Frasier LL, Holden S, Holden T, Schumacher JR, Leverson G, Anderson B et al (2016) Temporal trends in Postmastectomy radiation therapy and breast reconstruction associated with changes in National Comprehensive Cancer Network Guidelines. JAMA Oncol 2:95–101CrossRef

Ohri N, Sittig MP, Tsai CJ, Hwang ES, Mittendorf EA, Shi W et al (2018) Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: a National Cancer Data Base analysis. Cancer. 124:482–490CrossRef

Sasada S, Shien T, Iwata H (2018) Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan clinical oncology group survey. Breast Cancer

10.

Miyashita M, Tada H, Suzuki A, Watanabe G, Hirakawa H, Amari M et al (2017) Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era. Surg Oncol 26:163–170CrossRef

11.

McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK et al (2014) Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89:392–398CrossRef

12.

Moo TA, McMillan R, Lee M, Stempel M, Patil S, Ho A et al (2013) Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes. Ann Surg Oncol 20:3169–3174CrossRef

13.

Iwamoto T, Fukui N, Kinoshita T, Anan K, Niikura N, Kawai M et al (2016) Comprehensive prognostic report of the Japanese breast Cancer society registry in 2006. Breast Cancer 23:62–72CrossRef

14.

Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452–458CrossRef

15.

Overgaard M, Nielsen HM, Overgaard J (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82:247–253CrossRef

16.

Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567–575CrossRef

17.

Matsunuma R, Oguchi M, Fujikane T, Matsuura M, Sakai T, Kimura K et al (2012) Influence of lymphatic invasion on locoregional recurrence following mastectomy: indication for postmastectomy radiotherapy for breast cancer patients with one to three positive nodes. Int J Radiat Oncol Biol Phys 83:845–852CrossRef

18.

Tendulkar RD, Rehman S, Shukla ME, Reddy CA, Moore H, Budd GT et al (2012) Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys 83:e577–e581CrossRef

19.

Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R et al (2015) Biological subtype predicts risk of Locoregional recurrence after mastectomy and impact of Postmastectomy radiation in a large National Database. Int J Radiat Oncol Biol Phys 93:622–630CrossRef

20.

Jagsi R, Momoh AO, Qi J, Hamill JB, Billig J, Kim HM et al (2018) Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction. J Natl Cancer Inst 110

21.

Magill LJ, Robertson FP, Jell G, Mosahebi A, Keshtgar M (2017) Determining the outcomes of post-mastectomy radiation therapy delivered to the definitive implant in patients undergoing one- and two-stage implant-based breast reconstruction: a systematic review and meta-analysis. J Plast Reconstr Aesthet Surg 70:1329–1335CrossRef

Title: Therapeutic value of postmastectomy radiation therapy for T1–2 breast cancer with 1–3 positive lymph nodes
Authors: Yuri Kimura
Shinsuke Sasada
Noriko Goda
Keiko Kajitani
Akiko Emi
Norio Masumoto
Takayuki Kadoya
Morihito Okada
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Systemic Therapy
Breast Cancer
Breast Cancer
Published in: Journal of Radiation Oncology / Issue 3/2019
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-019-00402-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Evaluating improvements in cardiac dosimetry in breast radiotherapy and comparison of cardiac sparing techniques

Impact of choice of dose calculation algorithm on PTV and OAR doses in lung SBRT

Challenges in the re-irradiation of locally advanced head and neck cancers: outcomes and toxicities

Assessment of the alpha/beta ratio of the optic pathway to adjust hypofractionated stereotactic radiosurgery regimens for perioptic lesions

Definitive chemoradiation followed by stereotactic body radiotherapy boost for inoperable endometrial cancer

Long-term clinical outcomes of 538 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and external beam radiotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer